CHRS
Coherus Oncology·NASDAQ
--
--(--)
--
--(--)
6.68 / 10
Outperform
Analyst consensus is 100% Buy, with one Oppenheimer analyst showing a 100% historical win rate. Money‑flow score is 7.81 (good), showing positive inflows for overall, block, Small, Large and Extra‑large investors, while Medium investors are slightly negative.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-22
InstitutionOppenheimer
Times predicted1
Historical Win Rate100.0%
What is the market sentiment for CHRS?
- CHRS holds a Bullish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.68/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
